Wockhardt gets US FDA nod for generic anti-bacterial drug
- Indian scientists using artificial intelligence to predict early onset of Alzheimer’s
- People need to make preventive measure a habit if India is to become malaria-free by 2027: home insecticides makers
- Bollywood is in love with biopics. But will it last?
- Flipkart wins relief over tax on discounts
- Why homebuyers can’t expect any RERA relief soon
New Delhi: Drug firm Wockhardt has received approval from the US health regulator to market generic version of Wyeth’s Zosyn, used for treating bacterial infections, in the American market.
The application for the product to the US Food and Drug Administration (USFDA) was made by the company’s subsidiary Wockhardt Bio AG, the Mumbai-based company said in a regulatory filing.
“Wockhardt Bio AG had filed this abbreviated new drug application (ANDA) in collaboration with Fresinius Kabi, Italy (FKAI) where the product development was completed,” it added.
The ANDA will be manufactured commercially at FKAI, Mitim, Italy, it said. Wockhardt stock closed 2.54% down at Rs727.60 on BSE.